Nurtec ODT costs roughly $125 per tablet at list price, which works out to about $1,363 for a single eight-tablet pack at a retail pharmacy. That makes it one of the most expensive migraine medications on the market, and the price comes down to a combination of factors: the massive acquisition costs Pfizer needs to recoup, the drug’s unique clinical profile, the lack of generic competition, and an insurance landscape that makes the sticker price feel even worse for patients caught in coverage gaps.
What You’re Actually Paying
At a wholesale acquisition cost of approximately $125 per tablet, Nurtec is priced in a similar range to other newer migraine drugs in the CGRP class. Annual treatment costs for these medications are steep across the board. One cost-effectiveness analysis published in The American Journal of Managed Care estimated annual costs of roughly $79,500 for rimegepant (Nurtec), $74,800 for ubrogepant (Ubrelvy), and $92,200 for zavegepant (Zavzpret), compared to about $53,800 for standard migraine care. These figures factor in a 30% discount from average wholesale pricing, meaning they already account for some rebates and discounts that happen behind the scenes.
For comparison, generic triptans like sumatriptan can cost as little as a few dollars per pill. That price gap is the core of the sticker shock most patients experience.
Pfizer Paid $11.6 Billion for This Drug
In 2022, Pfizer acquired Biohaven Pharmaceuticals, the company that developed Nurtec, for approximately $11.6 billion in cash, paying $148.50 per share. That came on top of a $350 million investment Pfizer had already made the year before to help commercialize the drug outside the United States. Pharmaceutical companies price drugs to recover these acquisition and development costs within the window before patents expire and generics enter the market. With that much capital on the line, Pfizer has strong financial incentive to keep Nurtec’s price high for as long as it holds market exclusivity.
Why Nurtec Costs More Than Triptans
Part of the pricing reflects genuine clinical differences. Triptans have been the standard migraine treatment for decades, but roughly one-third of patients don’t respond well to them, and more than 20% of migraine patients have cardiovascular conditions that make triptans unsafe. Triptans work by constricting blood vessels, which is a problem for anyone with heart disease, a history of stroke, or uncontrolled high blood pressure.
Nurtec works through an entirely different mechanism. It blocks a protein involved in migraine signaling without narrowing blood vessels at all. In lab testing on human coronary and cerebral arteries, rimegepant showed no vasoconstrictive properties at any concentration tested, while sumatriptan (the most common triptan) caused progressive, dose-dependent artery constriction. That safety profile opens the drug up to a large group of patients who previously had limited options.
Nurtec is also the only oral migraine medication approved for both treating active migraines and preventing them. That dual capability means some patients can use a single drug instead of juggling separate acute and preventive medications. It also comes as a dissolving tablet that doesn’t require water, which matters when a migraine is causing nausea and vomiting. These advantages are real, and pharmaceutical companies price accordingly when a drug serves patients that older, cheaper options can’t.
No Generic Competition Yet
Nurtec has no generic equivalent available. As a relatively new brand-name drug with patent protection, it faces competition only from other branded CGRP medications, all of which are priced at similarly high levels. Without generic alternatives to drive the price down, there’s no market pressure pushing Pfizer to lower costs. This is the same dynamic that keeps most specialty drugs expensive until their patents expire.
Insurance Hurdles That Add to the Cost
Even with insurance, getting Nurtec covered typically requires jumping through significant hoops. Most insurers place it on a high formulary tier and require prior authorization, meaning your doctor has to submit paperwork proving you need it. The requirements are extensive.
For acute migraine treatment, insurers commonly require that you’ve already tried and failed (or can’t tolerate) at least two different triptans before they’ll approve Nurtec. Some plans go further, requiring you to also try and fail Ubrelvy, the other oral CGRP drug, before covering Nurtec. For preventive use, the bar is even higher. You may need to demonstrate that you’ve tried and failed medications from at least two different preventive drug classes (such as beta-blockers, certain antidepressants, or anti-seizure drugs), plus a monthly injectable CGRP medication, plus another oral preventive CGRP drug.
These step-therapy requirements exist because insurers want patients to try cheaper alternatives first. But they also mean that patients who would benefit from Nurtec often spend months cycling through other medications before gaining coverage. During that time, or if coverage is denied, you’re looking at the full retail price.
Initial approvals also tend to expire after six months, meaning the prior authorization process may need to be repeated. Some plans also require that the prescription come from or be approved by a neurologist specifically, adding another access barrier for patients managed by primary care doctors.
What the Savings Card Actually Covers
Pfizer offers a copay savings card for Nurtec with a maximum annual benefit of $7,000. That sounds generous, but the eligibility restrictions are narrow. You must have private commercial insurance that already covers Nurtec. The card is not available to cash-paying patients, and anyone on Medicare, Medicaid, TRICARE, or Veterans Affairs coverage is excluded. If your insurance plan uses an accumulator adjustment or copay maximizer program (increasingly common), you’re also ineligible. These programs essentially prevent manufacturer copay cards from counting toward your annual deductible or out-of-pocket maximum.
For patients whose insurance covers Nurtec but whose benefits haven’t been verified yet, the card allows a one-time fill of up to 16 tablets at no cost. After that, the $7,000 annual cap applies to whatever your remaining copay or coinsurance amounts to. For patients with high-deductible plans, $7,000 may not fully cover a year’s worth of medication at list price, particularly if the drug is used for both acute and preventive treatment.
The Bigger Picture on CGRP Drug Pricing
Nurtec’s price isn’t an outlier within its drug class. All CGRP-targeted migraine medications, whether oral tablets or monthly injectables, carry similarly high price tags. The Institute for Clinical and Economic Review has found that rimegepant and ubrogepant are more cost-effective than some newer alternatives for patients who can’t use triptans, but “more cost-effective” in health economics still means expensive by everyday standards.
The fundamental issue is that Nurtec exists in a market segment with no generic alternatives, high development costs, and a patient population that often has no cheaper option that works for them. That combination gives manufacturers significant pricing power. Until patent expiration opens the door to generic rimegepant, the price is unlikely to drop meaningfully.